Literature DB >> 4916317

Lincomycin. XI. Synthesis and structure of clindamycin. A potent antibacterial agent.

R D Birkenmeyer, F Kagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4916317     DOI： 10.1021/jm00298a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  10 in total

1.  Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 2. Synthesis of 7(S)-7-deoxy-7-(4-morpholinocarbonylphenylthio)lincomycin and its 3-dimensional analysis with rRNA.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Takashi Watanabe; Mikio Yamamoto; Yoko Hirai; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2015-12-16       Impact factor: 2.649

2.  Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Yasuo Sato; Yoko Hirai; Yoshio Hayashi; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

3.  Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 4: synthesis of novel lincomycin analogs modified at the 6- and 7-positions and their potent antibacterial activities.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Kazutaka Ueda; Takashi Watanabe; Keiko Yamada; Takafumi Okutomi; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-05-31       Impact factor: 2.649

4.  Synthetic oxepanoprolinamide iboxamycin is active against Listeria monocytogenes despite the intrinsic resistance mediated by VgaL/Lmo0919 ABCF ATPase.

Authors:  Tetiana Brodiazhenko; Kathryn Jane Turnbull; Kelvin J Y Wu; Hiraku Takada; Ben I C Tresco; Tanel Tenson; Andrew G Myers; Vasili Hauryliuk
Journal:  JAC Antimicrob Resist       Date:  2022-06-17

5.  Synthesis and antibacterial activity of novel lincomycin derivatives. IV. Optimization of an N-6 substituent.

Authors:  Ko Kumura; Yoshinari Wakiyama; Kazutaka Ueda; Eijiro Umemura; Yoko Hirai; Keiko Yamada; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-11-08       Impact factor: 2.649

Review 6.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

Review 7.  Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.

Authors:  Chris Greening; F Hafna Ahmed; A Elaaf Mohamed; Brendon M Lee; Gunjan Pandey; Andrew C Warden; Colin Scott; John G Oakeshott; Matthew C Taylor; Colin J Jackson
Journal:  Microbiol Mol Biol Rev       Date:  2016-04-27       Impact factor: 11.056

8.  Synthesis and antibacterial activity of novel lincomycin derivatives. III. Optimization of a phenyl thiadiazole moiety.

Authors:  Ko Kumura; Yoshinari Wakiyama; Kazutaka Ueda; Eijiro Umemura; Takashi Watanabe; Mikio Yamamoto; Takuji Yoshida; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

9.  Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 1. Newly generated antibacterial activities against Gram-positive bacteria with erm gene by C-7 modification.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Kazutaka Ueda; Satomi Masaki; Megumi Kumura; Hideki Fushimi; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2015-12-16       Impact factor: 2.649

10.  A synthetic antibiotic class overcoming bacterial multidrug resistance.

Authors:  Matthew J Mitcheltree; Amarnath Pisipati; Egor A Syroegin; Katherine J Silvestre; Dorota Klepacki; Jeremy D Mason; Daniel W Terwilliger; Giambattista Testolin; Aditya R Pote; Kelvin J Y Wu; Richard Porter Ladley; Kelly Chatman; Alexander S Mankin; Yury S Polikanov; Andrew G Myers
Journal:  Nature       Date:  2021-10-27       Impact factor: 69.504
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.